Φορτώνει......
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
AIMS: Navoximod (GDC‐0919, NLG‐919) is a small molecule inhibitor of indoleamine‐2,3‐dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were to assess navoximod's absolute bioavailability (aBA), determine the mass...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Br J Clin Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6624388/ https://ncbi.nlm.nih.gov/pubmed/30973970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13961 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|